Novocure Ltd. (NVCR)

36.40
0.10 0.27
NASDAQ : Health Technology
Prev Close 36.50
Open 36.50
Day Low/High 36.45 / 36.75
52 Wk Low/High 16.10 / 36.75
Volume 18.74K
Avg Volume 917.10K
Exchange NASDAQ
Shares Outstanding 90.70M
Market Cap 3.23B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Novocure Appoints Pritesh Shah As Chief Commercial Officer

Novocure Appoints Pritesh Shah As Chief Commercial Officer

Novocure (NASDAQ:NVCR) announced today that Pritesh Shah has been appointed as Novocure's Chief Commercial Officer, reporting to Novocure's Chief Executive Officer Asaf Danziger.

Novocure To Report Second Quarter 2018 Financial Results

Novocure To Report Second Quarter 2018 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2018 on Thursday, July 26, 2018, before the U.

NovoCure's Charts Look Bullish

NovoCure's Charts Look Bullish

NovoCure started a strong rally in 2017 and continues to move up.

Under Armour, Cognex, Novocure: 'Mad Money' Lightning Round

Under Armour, Cognex, Novocure: 'Mad Money' Lightning Round

Jim Cramer weighs in on Under Armour, Cognex, Novocure, FireEye, Weight Watchers, Bristol-Meyers Squibb and Chegg.

The Name of the Game Is Growth: Cramer's 'Mad Money' Recap (Wednesday 6/20/18)

The Name of the Game Is Growth: Cramer's 'Mad Money' Recap (Wednesday 6/20/18)

Jim Cramer explains why the fulcrum for the financial markets is growth -- not tariffs, or the Fed, or interest rates.

NVCR Crosses Above Average Analyst Target

NVCR Crosses Above Average Analyst Target

In recent trading, shares of NovoCure Ltd have crossed above the average analyst 12-month target price of $31.80, changing hands for $31.95/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Novocure To Present INNOVATE-3 Phase 3 Pivotal Trial Design In Recurrent Ovarian Cancer At The American Society Of Clinical Oncology Annual Meeting 2018

Novocure To Present INNOVATE-3 Phase 3 Pivotal Trial Design In Recurrent Ovarian Cancer At The American Society Of Clinical Oncology Annual Meeting 2018

Novocure (NASDAQ: NVCR) will present today for the first time the design of its phase 3 pivotal trial of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer at the American Society of Clinical...

Novocure Reports First Quarter 2018 Financial Results And Provides Company Update

Novocure Reports First Quarter 2018 Financial Results And Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and year ended March 31, 2018, highlighting year-over-year growth in active patients and net revenues.

Novocure To Report First Quarter 2018 Financial Results

Novocure To Report First Quarter 2018 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2018 on Thursday, April 26, 2018, before the U.

First Week of NVCR May 18th Options Trading

First Week of NVCR May 18th Options Trading

Investors in NovoCure Ltd saw new options begin trading this week, for the May 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVCR options chain for the new May 18th contracts and identified one put and one call contract of particular interest.

NCCN Guidelines Recommend Optune In Combination With Temozolomide As A Category 1 Treatment For Newly Diagnosed Glioblastoma

NCCN Guidelines Recommend Optune In Combination With Temozolomide As A Category 1 Treatment For Newly Diagnosed Glioblastoma

Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to recommend Optune® in combination with temozolomide as a category 1 treatment...

Novocure Announces 35 Presentations On Tumor Treating Fields At The American Association For Cancer Research Annual Meeting 2018

Novocure Announces 35 Presentations On Tumor Treating Fields At The American Association For Cancer Research Annual Meeting 2018

Novocure (NASDAQ: NVCR) announced today 35 presentations on Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2018, April 14 through April 18, in Chicago.

Big Earnings Week Ahead: Cramer's 'Mad Money' Recap (Monday 2/26/18)

Big Earnings Week Ahead: Cramer's 'Mad Money' Recap (Monday 2/26/18)

Jim Cramer is keeping a close eye on retail earnings this week, along with testimony from new Fed Chair Jerome Powell.

Novocure Reports Fourth Quarter And Full Year 2017 Financial Results And Provides Company Update

Novocure Reports Fourth Quarter And Full Year 2017 Financial Results And Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and year ended December 31, 2017, highlighting year-over-year and sequential growth in active patients and net revenues.

Novocure Secures New $150 Million Non-Dilutive Term Loan Financing

Novocure Secures New $150 Million Non-Dilutive Term Loan Financing

Novocure (NASDAQ: NVCR) announced today that it has entered into a $150 million term loan agreement with BioPharma Credit PLC (LSE: BPCR), an investment fund managed by Pharmakon Advisors, LP, with proceeds used to pay in...

JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival Without Negatively Influencing Health-Related Quality Of Life Compared To Temozolomide Alone In Newly Diagnosed GBM Patients

JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival Without Negatively Influencing Health-Related Quality Of Life Compared To Temozolomide Alone In Newly Diagnosed GBM Patients

Novocure (NASDAQ: NVCR) announced today that a detailed quality of life analysis of Novocure's EF-14 phase 3 pivotal trial of Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma (GBM)...

First Week of September 21st Options Trading For NovoCure (NVCR)

First Week of September 21st Options Trading For NovoCure (NVCR)

Investors in NovoCure Ltd saw new options begin trading this week, for the September 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Novocure Announces Fourth Quarter And Full Year 2017 Operating Statistics And Preliminary Revenue

Novocure Announces Fourth Quarter And Full Year 2017 Operating Statistics And Preliminary Revenue

Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited revenue for the fourth quarter and full year 2017.

Novocure To Participate In 36th Annual J.P. Morgan Healthcare Conference

Novocure To Participate In 36th Annual J.P. Morgan Healthcare Conference

Novocure (NASDAQ: NVCR) announced today that it will participate in the 36th Annual J.

Novocure Receives FDA IDE Approval For Its PANOVA 3 Phase 3 Pivotal Clinical Trial In Advanced Pancreatic Cancer

Novocure Receives FDA IDE Approval For Its PANOVA 3 Phase 3 Pivotal Clinical Trial In Advanced Pancreatic Cancer

Novocure (NASDAQ: NVCR) announced today that it has received a U.S.

Novocure Receives Reimbursement Approval For Optune® In Japan For The Treatment Of Newly Diagnosed Glioblastoma

Novocure Receives Reimbursement Approval For Optune® In Japan For The Treatment Of Newly Diagnosed Glioblastoma

Novocure (NASDAQ:NVCR) announced today that the Japanese Ministry of Health, Labour and Welfare has approved the recommendation by Japan's Central Social Insurance Medical Council (Chuikyo) to provide reimbursement for...

Novocure To Present At Two Upcoming Investor Conferences In December

Novocure To Present At Two Upcoming Investor Conferences In December

Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences in December.

Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers

Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers

Oncology firm released results that show increased compliance with Optune predicted increased survival in patients with glioblastoma, a form of brain cancer.

Patients Who Used Optune® More Than 90 Percent Of The Time Had The Greatest Chance Of Survival In Novocure's EF-14 Trial: A Median Survival Of 24.9 Months From Randomization And A Five-Year Survival Of 29.3 Percent

Patients Who Used Optune® More Than 90 Percent Of The Time Had The Greatest Chance Of Survival In Novocure's EF-14 Trial: A Median Survival Of 24.9 Months From Randomization And A Five-Year Survival Of 29.3 Percent

Novocure (NASDAQ:NVCR) announced today results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance with Optune predicted increased survival in glioblastoma (GBM)...

Novocure Announces 28 Presentations On Tumor Treating Fields From Externally Led Clinical Research And Analysis At 22nd Annual Meeting Of The Society For Neuro-Oncology

Novocure Announces 28 Presentations On Tumor Treating Fields From Externally Led Clinical Research And Analysis At 22nd Annual Meeting Of The Society For Neuro-Oncology

Novocure (NASDAQ:NVCR) announced today 28 presentations on Tumor Treating Fields from externally led clinical research and analysis at the 22nd Annual Meeting of the Society for Neuro-Oncology (SNO), November 16 through...

Novocure Announces 13 Preclinical Presentations Highlighting Data On Tumor Treating Fields' Mechanism Of Action At 22nd Annual Meeting Of The Society For Neuro-Oncology

Novocure Announces 13 Preclinical Presentations Highlighting Data On Tumor Treating Fields' Mechanism Of Action At 22nd Annual Meeting Of The Society For Neuro-Oncology

Novocure (NASDAQ:NVCR) announced today 13 preclinical presentations highlighting data on Tumor Treating Fields' mechanism of action at the 22nd Annual Meeting of the Society for Neuro-Oncology (SNO), November 16 through...

Novocure Announces Six Clinical Presentations On Novocure's Phase 3 Pivotal EF-14 Trial Data In Newly Diagnosed Glioblastoma At 22nd Annual Meeting Of The Society For Neuro-Oncology

Novocure Announces Six Clinical Presentations On Novocure's Phase 3 Pivotal EF-14 Trial Data In Newly Diagnosed Glioblastoma At 22nd Annual Meeting Of The Society For Neuro-Oncology

Novocure (NASDAQ: NVCR) announced today six clinical presentations on Novocure's phase 3 pivotal EF-14 trial data in newly diagnosed glioblastoma (GBM) at the 22nd Annual Meeting of the Society for Neuro-Oncology (SNO),...

Novocure Reports Third Quarter 2017 Financial Results And Provides Company Update

Novocure Reports Third Quarter 2017 Financial Results And Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the three and nine months ended September 30, 2017, highlighting year-over-year and sequential growth in active patients and net revenues.

TheStreet Quant Rating: D+ (Sell)